ArticleJournal for immunotherapy of cancer2023

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.

Omid Hamid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.